• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Introduction to checkpoint inhibitors and cancer immunotherapy.

作者信息

Sharpe Arlene H

机构信息

Department of Microbiology and Immunobiology, and Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Immunol Rev. 2017 Mar;276(1):5-8. doi: 10.1111/imr.12531.

DOI:10.1111/imr.12531
PMID:28258698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5362112/
Abstract
摘要

相似文献

1
Introduction to checkpoint inhibitors and cancer immunotherapy.检查点抑制剂与癌症免疫疗法简介。
Immunol Rev. 2017 Mar;276(1):5-8. doi: 10.1111/imr.12531.
2
Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.在检查点阻断时代的癌症疫苗：佐剂才是关键。
Curr Opin Immunol. 2017 Aug;47:103-109. doi: 10.1016/j.coi.2017.07.015. Epub 2017 Aug 12.
3
Myeloid-derived suppressor cells: Multi-talented immune suppressive cells that can be either helpful or harmful.髓源性抑制细胞：具有多种功能的免疫抑制细胞，其作用可能有益也可能有害。
Cell Immunol. 2021 Jul;365:104374. doi: 10.1016/j.cellimm.2021.104374. Epub 2021 Apr 27.
4
Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.癌症诱导的异质性免疫抑制肿瘤微环境及其个性化调控。
Int Immunol. 2016 Aug;28(8):393-9. doi: 10.1093/intimm/dxw030. Epub 2016 Jul 8.
5
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.移植环境中靶向共抑制和共刺激途径的研究进展：癌症免疫治疗的阴阳两面
Immunol Rev. 2017 Mar;276(1):192-212. doi: 10.1111/imr.12523.
6
New insight into cancer immunotherapy.癌症免疫疗法的新见解。
Allergol Immunopathol (Madr). 2017 Dec;45 Suppl 1:50-55. doi: 10.1016/j.aller.2017.09.013. Epub 2017 Nov 3.
7
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.靶向肿瘤代谢：提高免疫疗法的新挑战。
Front Immunol. 2018 Feb 23;9:353. doi: 10.3389/fimmu.2018.00353. eCollection 2018.
8
Autoimmune Cardiotoxicity of Cancer Immunotherapy.癌症免疫治疗的自身免疫性心脏毒性。
Trends Immunol. 2017 Feb;38(2):77-78. doi: 10.1016/j.it.2016.11.007. Epub 2016 Dec 2.
9
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.B7-CD28免疫检查点家族的第三组：HHLA2、TMIGD2、B7x和B7-H3。
Immunol Rev. 2017 Mar;276(1):26-39. doi: 10.1111/imr.12521.
10
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.癌症治疗中的免疫检查点抑制剂：以 T 调节细胞为重点。
Immunol Cell Biol. 2018 Jan;96(1):21-33. doi: 10.1111/imcb.1003. Epub 2017 Nov 17.

引用本文的文献

1
A Human Tumor-Immune Organoid Model of Glioblastoma.一种胶质母细胞瘤的人类肿瘤-免疫类器官模型。
bioRxiv. 2025 Jun 20:2025.06.16.660009. doi: 10.1101/2025.06.16.660009.
2
Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.用于癌症免疫治疗的细菌介导的肿瘤相关巨噬细胞原位工程
Cancers (Basel). 2025 Feb 20;17(5):723. doi: 10.3390/cancers17050723.
3
Lenvatinib Maintenance Therapy After Complete Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: Alternative Strategy in a Resource-limited Setting.在肝细胞癌和门静脉肿瘤血栓形成中，阿替利珠单抗联合贝伐单抗完全缓解后使用乐伐替尼维持治疗：资源有限环境下的替代策略
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102455. doi: 10.1016/j.jceh.2024.102455. Epub 2024 Nov 13.
4
The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation.免疫检查点阻断对异基因造血干细胞移植结局的影响。
Front Immunol. 2024 Nov 20;15:1491330. doi: 10.3389/fimmu.2024.1491330. eCollection 2024.
5
Immune Checkpoint Inhibitor Associated Rheumatoid Arthritis.免疫检查点抑制剂相关的类风湿关节炎
Curr Rheumatol Rep. 2024 Nov 26;27(1):3. doi: 10.1007/s11926-024-01173-6.
6
Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report.肝细胞癌伴门静脉癌栓患者停用阿替利珠单抗-贝伐单抗治疗后的持久完全缓解：首例报告
J Liver Cancer. 2025 Mar;25(1):134-137. doi: 10.17998/jlc.2024.09.26. Epub 2024 Nov 5.
7
Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases.OncoTherad®（MRB-CFI-1）纳米免疫疗法对非肌肉浸润性膀胱癌肿瘤微环境的调节作用：对肿瘤相关巨噬细胞、肿瘤浸润淋巴细胞和单胺氧化酶的影响。
Med Oncol. 2024 Oct 15;41(11):287. doi: 10.1007/s12032-024-02533-z.
8
The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies.急性髓系白血病的免疫抵抗特征及当前免疫治疗策略
Cancers (Basel). 2024 Jul 23;16(15):2615. doi: 10.3390/cancers16152615.
9
Development of small molecule drugs targeting immune checkpoints.针对免疫检查点的小分子药物的研发。
Cancer Biol Med. 2024 May 9;21(5):382-99. doi: 10.20892/j.issn.2095-3941.2024.0034.
10
TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes.TIGIT 在自身免疫性糖尿病中抑制 PD1 信号后作为免疫检查点发挥作用。
Front Immunol. 2024 Mar 12;15:1370907. doi: 10.3389/fimmu.2024.1370907. eCollection 2024.

本文引用的文献

1
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.CD47-SIRPα信号轴作为癌症中的一种固有免疫检查点。
Immunol Rev. 2017 Mar;276(1):145-164. doi: 10.1111/imr.12527.
2
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.移植环境中靶向共抑制和共刺激途径的研究进展：癌症免疫治疗的阴阳两面
Immunol Rev. 2017 Mar;276(1):192-212. doi: 10.1111/imr.12523.
3
Potential targeting of B7-H4 for the treatment of cancer.B7-H4在癌症治疗中的潜在靶向作用。
Immunol Rev. 2017 Mar;276(1):40-51. doi: 10.1111/imr.12530.
4
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.胞外核苷酸酶CD39和CD73：新型检查点抑制剂靶点。
Immunol Rev. 2017 Mar;276(1):121-144. doi: 10.1111/imr.12528.
5
New checkpoints in cancer immunotherapy.癌症免疫疗法中的新检查点。
Immunol Rev. 2017 Mar;276(1):52-65. doi: 10.1111/imr.12524.
6
Tim-3 and its role in regulating anti-tumor immunity.Tim-3及其在调节抗肿瘤免疫中的作用。
Immunol Rev. 2017 Mar;276(1):97-111. doi: 10.1111/imr.12520.
7
Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.在维持免疫耐受的同时进行共抑制阻断：胶质母细胞瘤的检查点抑制剂
Immunol Rev. 2017 Mar;276(1):9-25. doi: 10.1111/imr.12529.
8
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.TIGIT和CD96：癌症免疫治疗的新型检查点受体靶点
Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518.
9
Immunoregulatory functions of VISTA.VISTA的免疫调节功能。
Immunol Rev. 2017 Mar;276(1):66-79. doi: 10.1111/imr.12525.
10
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.B7-CD28免疫检查点家族的第三组：HHLA2、TMIGD2、B7x和B7-H3。
Immunol Rev. 2017 Mar;276(1):26-39. doi: 10.1111/imr.12521.